NVCR241220C35000
- 0.74
- -0.36-32.73%
Novocure Newsroom
A Quick Look at Today's Ratings for Novocure(NVCR.US), With a Forecast Between $30 to $40
NovoCure Limited (NASDAQ:NVCR) Looks Just Right With A 84% Price Jump
Novocure Is Maintained at Buy by HC Wainwright & Co.
Zai Lab, Novocure Announce PANOVA-3 Trial Met Primary Endpoint
Novocure Shares Jump Nearly 50% on Trial Results for Pancreatic Cancer Therapy
U.S. Small Caps Close Mixed As Novocure Lead, Archer Aviation Lags
12 Health Care Stocks Moving In Monday's Pre-Market Session
Dow Dips 150 Points; ISM Manufacturing PMI Tops Estimates
Update: NovoCure's Shares Rise as Pancreatic Cancer Trial Meets Primary Endpoint
HC Wainwright & Co. Reiterates Buy on NovoCure, Raises Price Target to $38
Positive Outlook for NovoCure: Buy Rating Backed by Successful PANOVA-3 Trial and Promising Market Potential
Leerink Partners Adjusts NovoCure Price Target to $33 From $28, Maintains Outperform Rating
XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday
NovoCure Up Over 30%, on Pace for Largest Percent Increase Since January 2023 -- Data Talk
NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients
Express News | Novocure Ltd : Wedbush Raises Target Price to $29 From $24
Sector Update: Health Care Stocks Mixed Pre-Bell Monday
This Gap Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Monday Ahead of Week Promising Crucial Economic Data
Express News | NocoCure Shares Are Trading Higher After the Company Announced Its Phase 3 PANOVA-Trial Met Its Primary Endpoint and Demonstrated a Statistically Significant Improvement in Its Median Overall Survival Rate